Study on short and mid-term effects of bereprost sodium combined with cyclophosphamide in the treatment of nephrotic syndrome

Objective:To analyze the short and mid-term effects of beraprost sodium combined with cyclophosphamide in the treatment of nephrotic syndrome(NS).

MethodsNinety-six patients with NS from January 2015 to May 2017 were randomly divided into the control group and observation group(48 cases in each group).The control group was treated with the routine comprehensive method, and the observation group was additionally treated with beraprostis sodium combined with cyclophosphamide based on control group.The disease control rate, recurrence rate, renal function indexcreatinine clearance(CCR), albumin (ALB), creatinine (Scr), 24h urinary protein excretion rate(UAER) and urea nitrogen (BUN), blood lipid indicatorstriglyceride(TG) and total cholesterol(TC), coagulation parametersD-dimer(D-D) and fibrinogen(FIB), P-glycoprotein 170(P-gp170) and incidence arte of adverse reactions were compared between two groups.

ResultsThe disease control rate(93.75%) in observation group was better than that in control group(68.75%)(P < 0.01).After 6 months and 1 year of treatment, the recurrence rates in observation group(2.08% and 4.17%) were lower than those in control group(16.67% and 18.75%), respectively(P < 0.05).After treatment, the CCR and ALB levels in observation group were significnatly higher than those in control group, while the levels of Scr, UAER and BUN in observation group were significnatly lower than those in control group(P < 0.05).After treatment, the levels of TG and TC in observation group were significnatly lower than those in control group(P < 0.05), and the levels of TG and TC in two groups were significnatly lower than those before treatment(P < 0.05).After treatment, the P-gp170 levels in two groups increased compared with before treatment, but the increasing degree of which in observation group was smaller than that in control group(P < 0.05).There was no statistical significance in the incidence rate of adverse reactions between the observation group(4.17%) and control group(8.33%) (P>0.05).

ConclusionsThe bereprost sodium combined with cyclophosphamide in the treatment of NS can improve the multidrug resistance, optimize blood lipid metabolism, improve renal function and coagulation function, increase disease control rate, reduce the recurrence of the disease, and is safe and reliable.